KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EPS (Weighted Average and Diluted) (2020 - 2025)

Ginkgo Bioworks Holdings' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$1.42 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 27.55% year-over-year to -$1.42; the TTM value through Dec 2025 reached -$5.65, up 46.65%, while the annual FY2025 figure was -$5.64, 46.49% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.42 in Q4 2025 per DNA's latest filing, up from -$1.45 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.04 in Q2 2021 to a low of -$49.01 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$4.13, with a median of -$1.21 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 91.27% in 2023, then crashed 4600.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.21 in 2021, then crashed by 3950.41% to -$49.01 in 2022, then surged by 91.27% to -$4.28 in 2023, then skyrocketed by 54.21% to -$1.96 in 2024, then grew by 27.55% to -$1.42 in 2025.
  • Per Business Quant, the three most recent readings for DNA's EPS (Weighted Average and Diluted) are -$1.42 (Q4 2025), -$1.45 (Q3 2025), and -$1.1 (Q2 2025).